

### Thursday, 18.05.2023

- 17:30** Registration
- 18:00** Opening
- 18:30** **Kim Stegmaier** (keynote speaker)  
Ewing Sarcoma – A Goldilocks Tale
- 19:30** Welcome reception

### Friday, 19.05.2023

#### Session 1

- 08:30** Registration
- 09:00** **Isidro Cortes-Ciriano** (guest speaker)  
Malignant peripheral nerve sheath tumour (MPNST) evolution is defined by recurrent copy number aberrations that are detectable in cell-free DNA and predict clinical outcome
- 09:30** **Beate Rinner**  
Patient-derived translocation-related sarcoma models enables translational research and tailored therapies
- 09:45** **Nikolaus Mandlbürger**  
Potentials of epigenetic analysis of cell-free DNA for liquid biopsies in Ewing sarcoma
- 10:00** **Natacha Entz-Werlé**  
Osteoblastic-gene signature to predict survival in pediatric osteosarcoma (OS) and to follow patients towards liquid biopsy: a collaborative work in OS2006 protocol.
- 10:15** **Flash Talks\***
- 10:45** Coffee Break


#### Session 2

- 11:15** **Anna Obenauf** (guest speaker)  
Towards rational combination therapies: Understanding tumor evolution during therapy response and resistance
- 11:45** **Marie Castets**  
Targeting cell death in rhabdomyosarcoma: new perspectives from organoid technology.
- 12:00** **Martin Distel**  
cPLA2 expression correlates with enhanced invasion of osteosarcoma cells in vivo
- 12:15** **Birgit Lohberger**  
Cellular and molecular biological alterations after proton and carbon ion irradiation in human chondrosarcoma cells with respect to DNA repair and radiosensitivity
- 12:30** **Flash Talks\***
- 13:00** Lunch Break

#### Session 3

- 14:00** **Silvia Stacchiotti** (guest speaker)  
New treatments for ultra-rare sarcomas
- 14:30** **Sofia Avnet**  
Gut microbiota dynamics in osteosarcoma patients undergoing chemotherapy treatment and its association with response to therapy
- 14:45** **Sara Sánchez Molina**  
KDM6 demethylases mediate EWSR1-FLI1-driven oncogenic transformation in Ewing Sarcoma
- 15:00** **Aykut Uren**  
Piperacetazine directly binds to PAX3::FOXO1 and inhibits its transcriptional activity in rhabdomyosarcoma cells





**15:15 Flash Talks\***

**15:45** Coffee Break

### Session 4

**16:15 Florian Grebien** (guest speaker)

Oncogenic mechanisms of fusion proteins in pediatric cancer

**16:45 Sibylle Mitnacht**

Therapeutics profiling identifies selective vulnerabilities in standard-of-care agent unresponsive osteosarcoma

**17:00 Christoph Hafemeister**

Tracking Ewing Sarcoma origin using Developmental Genomics

**17:15 Julian Musa**

Chromosome 8 gain drives poor patient outcome via expression of 4E-BP1 in Ewing sarcoma

**17:30 Flash Talks\***

**19:30** Social Event

## Saturday, 20.05.2023

---

### Session 5

**08:30** Registration

**09:00 Georg Winter** (guest speaker)

Targeting gene control in cancer via small-molecule degraders

**09:30 Ian Lock**

Identifying non-canonical p53 functions that mediate tumor suppression

**09:45 Javier Munoz-Garcia**

ETV4 controls the dormancy of osteosarcoma cells

**10:00 Kazuhiko Matsuoka**

Activation of c-Fos and p53 inactivation drives recurrent/metastatic Osteosarcoma

**10:15 Flash Talks\***

**10:45** Coffee Break

### Session 6

**11:00 Christoph Bock** (guest speaker)

Programmed Cells? Machine learning for precision medicine

**11:30 Antonin Marchais**

Deciphering the Spatial Complexity of Osteosarcoma Lung Metastases: Unveiling Metaphyseal-Like Tumor Architecture and Recurrent Immunosuppression


**11:45 Nezha Benabdallah**

An autoregulatory feedback loop converging on H2A ubiquitination drives synovial sarcoma

**12:00** Closing Remarks

**12:15** End





### \*Flash Talks

#### Session 1

- Maria Cristina Manara** Influence of CD99 triggering on macrophage functions and tumor cell killing in Ewing sarcoma
- Margherita Cortini** Endogenous Extracellular Matrix Regulates the Response of Osteosarcoma 3D Spheroids to Doxorubicin
- Veveeyan Suresh** Ewing sarcoma screening model to identify EWS::FLI1 modulators and their consequences on tumorigenesis
- Valerie Fock** Linking EWS::FLI1 thresholds to distinct transcriptional programs and functional cell states in Ewing sarcoma
- Martha Zylka** Exploration of lung metastasis in pediatric solid tumors through in vitro modeling
- Tyler Barr** Oncolytic virus therapy for Ewing sarcoma
- Snehadri Sinha** Osteosarcoma-derived extracellular vesicle treatments to 2D and 3D cultures of mesenchymal stem cells

#### Session 2

- Djenana Vejzovic** Thinking outside the box: patient-derived sarcoma models
- Linda Vidova** Identifying the genetic drivers of cancer stem cells for regrowth and metastasis of soft tissue sarcoma
- Tyler Barr** Oncolytic herpes simplex virus immunotherapy for osteosarcoma
- Borja Gallego** Multi-omics Approach to Address Doxorubicin Resistance in Bone Sarcomas
- Akanksha Farswan** The Genomic Landscape of Clear Cell Sarcoma
- Katie Finegan** Targeting ERK5 as a new immunotherapy approach for osteosarcoma
- Lucia Cottone** Aberrant paracrine signalling underlies the oncohistone-driven giant cell tumour of bone


#### Session 3

- Marcus Tötzl** Highly multiplexed large-scale dissection of epigenetic dysregulation in Ewing sarcoma.
- Sybille Mittnacht** Towards a Living Biobank for Sarcoma in the Head and Neck Region
- Carmen Huergo** Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma
- Fernando Lecanda** Development of new murine sarcoma models
- Carmo Martins** Derivation and characterization of a novel pediatric mesenchymal chondrosarcoma cell line carrying the pathognomonic HEY1::NCOA2 fusion
- Živa Zajec** Discovery and optimisation of novel Hsp90 C-terminal inhibitors with activity against Ewing sarcoma
- Elisabet Figuerola Bou** The neddylation inhibitor Pevonedistat alters RING1B activity in Ewing sarcoma

#### Session 4

- Javier Munoz-Garcia** New antibodies against IL-34 reduce in vitro and in vivo tumor cell proliferation in osteosarcoma models
- Vineet Dalal** Distinct roles for Polycomb repressive complexes in synovial sarcoma
- Miriam Arrulo** Identification of novel therapies for metastatic soft tissue sarcoma
- Dzohara Cabria Murillo** CRISPR/Cas9 dropout screening to identify genetic vulnerabilities in osteosarcoma
- Anna Ehlers** Characterization of chemoresistance mechanisms in Ewing sarcoma
- Dominique Heymann** CIRCUS: Circulating tumour cells in soft tissue sarcoma – a pilot study
- Anna Loboda** Pathing the way: HDAC and BET inhibitor combination as a novel treatment option for Ewing Sarcoma.
- Michael Dack** Repurposing the Repurposed: Exploring Heme-Oxygenase 1 Activity in Osteosarcoma Metastasis





# Program

## Session 5

- Fernando Lecanda** Immune landscape of lung metastases in immunocompetent osteosarcoma models
- Caterina Sturtzel** Advanced high-content imaging-based phenotypic drug screening on pediatric cancer zebrafish xenografts
- Jaka Dernovšek** New Hsp90 C-terminal domain inhibitor TSF-15 hinders tumour growth in a larval Ewing sarcoma zebrafish xenograft model
- Adam Varady** Spatially precise eradication of cancer cells in vivo using a photoswitchable microtubule inhibitor
- Denis Cochonneau** Detection of circulating tumor cells (CTCs) in two rare soft tissue tumors: PEComa & Desmoplastic Small Round Cell Tumor (DSRT)
- Joanna Kitlinska** Neuropeptide Y and its Y5 receptor in Ewing sarcoma metastasis
- Natacha Entz-Werlé** Anti-GD2 synergizes with hypoxia pathway targeting to block osteosarcoma cell proliferation and migration
- Per Sonne Holm** Targeting BRD4 and CDK4/6 uncovered key functionalities in the adenoviral life cycle and enhances the oncolytic potency of XVir-N-31

